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mutation, a diagnosis of MDS-RS may be deﬁned with RS inyelodysplastic syndromes (MDS) represent a group of clonal
ematopoietic stem cell disorders in which cytopenias of
ariable severity are associated with dysplastic changes of
ematopoietic precursors, and a higher risk of progression to
cute myeloid leukemia (AML).1 Besides dysplasia, the pres-
nce of ring sideroblasts (RS) has long been recognized as an
mportant morphologic feature of MDS; it used to deﬁne a sub-
et of patients within this group. Accordingly, the World Health
rganization (WHO) criteria revised in 2008 deﬁned refractory
nemia with ring sideroblasts (RA-SR) as a speciﬁc MDS sub-
roup, morphologically characterized by erythroid dysplasia
nd the presence of at least 15% RS in bone marrow smears.2
However, seminal studies published within the last ﬁve
ears have changed concepts and diagnostic deﬁnitions in
he ﬁeld of myeloid malignancies swiftly. Among these stud-
es, made possible by the development of high-throughput
equencing technologies, the description of mutations associ-
ted with MDS  and AML  in large patient cohorts,3–5 followed
y the demonstration that some of these mutations are also
resent (though with a lower allele burden) in individuals
ithout evident hematologic alterations,6–8 led to the proposal
f a new pathological category termed clonal hematopoiesis
f indeterminate potential (CHIP).9 This could be conceptually
iewed for myeloid neoplasms, as monoclonal gammopa-
hy of undetermined signiﬁcance is for multiple myeloma.
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Revista Brasileira de Hematologia e Hemoterapia (RBHH)10
– these studies also resulted in the description of the ﬁrst
association between an acquired mutation and a speciﬁc mor-
phologic abnormality of hematopoietic precursors in MDS.
High-throughput whole genome sequencing studies
revealed that mutations in genes involved in RNA splicing
are found in ∼45–85% of patients with MDS.  In particular,
somatic mutations of splicing factor3b subunit 1 (SF3B1) have
been identiﬁed in ∼60–80% of MDS-RS patients4,5 with an
extremely high predictive value for the disease phenotype
with RS, as SF3B1 is emerging as the ﬁrst gene to be strongly
associated with a speciﬁc morphological feature of MDS.11
Moreover, MDS  patients carrying SF3B1 mutations present a
fairly homogeneous disease phenotype often characterized by
isolated erythroid dysplasia, signiﬁcant erythroid dysplasia,
and high proportion of RS. Even more  importantly, these
patients present signiﬁcantly better survival and lower risk
of progression to AML.11,12 Together, these data supported a
signiﬁcant change in the revised WHO  classiﬁcation of MDS
in 2016, which established that, in the presence of a SF3B1):320–324.
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as few as 5% of nucleated erythroid cells, with the former
threshold of 15% RS reserved for cases lacking a demon-
strable SF3B1 mutation.13 These patients will be classiﬁed
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as ‘MDS with single lineage dysplasia and ring sideroblasts
(MDS-RSSLD)’ or ‘MDS with multilineage dysplasia and ring
sideroblasts (MDS-RSMLD)’.13
It is in this changing context that Donaires et al. present
a study in which SF3B1 mutations were screened in 91 MDS
patients from two distinct geographical areas of Brazil, using a
strategy targeting the most frequently mutated exons of SF3B1
by direct Sanger sequencing.10 In total, 7% of patients pre-
sented heterozygous SF3B1 mutations, all of them with RS.
The proportion of patients presenting SF3B1 mutations was
somewhat lower than reported in Europe and North America,
a ﬁnding that the authors speculate to be associated with the
heterogeneous background of the Brazilian population, or to
the fact that only mutation hotspots were evaluated in the
SF3B1 gene using their screening strategy. The authors also
provide a detailed review of the cellular and molecular mech-
anisms by which SF3B1 mutations lead to RS, and an in silico
simulation of the putative consequences of each mutation
that they found in the function of SF3B1 protein.
The quick impact of the identiﬁcation of the association
of SF3B1 mutations with RS on classical diagnostic criteria
for MDS  illustrate how fast new molecular biology ﬁndings
can inﬂuence the practice of the general hematologist. Well-
known challenges in the differential diagnosis of MDS,14 and
the prospects that new molecular data also pave the way
to improve risk stratiﬁcation and treatment strategies15 cor-
roborate the importance of studies addressing the molecular
pathogenesis of myeloid malignancies and in particular of
MDS.
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